Stock Watch: Reclassified Revenues Help Novartis's Fourth Quarter
Last-Minute Revenue Reclassifications Are Probably Not Reproducible
Executive Summary
A one-off revenue rabbit brought out of the hat may have helped Novartis's fourth-quarter sales but its analysts and investors were not impressed.
You may also be interested in...
Stock Watch: Johnson & Johnson's Fast And Slow Lanes
With all the commentary on J&J’s acquisition strategy and its consumer spin-off, the fourth-quarter performance of its pharmaceutical division went almost unnoticed.
Novartis Opts For Alliance Rather Than Acquisition With Alnylam
The announcement that the Swiss giant is collaborating again with Alnylam could spark fresh speculation that the firms are moving closer to a merger – or not.
Stock Watch: One Acquisition Does Not Make A Biotech M&A Boom
Another blow-out quarter from Pfizer provided the impetus for an acquisition. But the history of recent commercial-stage biotech transactions and the risky nature of all early-stage companies suggest that the floodgates will not burst open.